Your browser is no longer supported. Please, upgrade your browser.
Settings
IMMU Immunomedics, Inc. daily Stock Chart
IMMU [NASD]
Immunomedics, Inc.
Index- P/E- EPS (ttm)-0.72 Insider Own3.20% Shs Outstand101.61M Perf Week0.60%
Market Cap514.15M Forward P/E337.33 EPS next Y0.02 Insider Trans-1.21% Shs Float99.71M Perf Month16.86%
Income-70.50M PEG- EPS next Q-0.13 Inst Own58.80% Short Float22.86% Perf Quarter68.67%
Sales3.00M P/S171.38 EPS this Y-21.10% Inst Trans20.26% Short Ratio7.65 Perf Half Y75.09%
Book/sh-0.71 P/B- EPS next Y103.90% ROA-129.20% Target Price7.50 Perf Year132.11%
Cash/sh0.46 P/C11.03 EPS next 5Y- ROE113.90% 52W Range1.91 - 5.89 Perf YTD37.87%
Dividend- P/FCF- EPS past 5Y-26.90% ROI-132.90% 52W High-14.09% Beta1.73
Dividend %- Quick Ratio1.70 Sales past 5Y-26.10% Gross Margin54.70% 52W Low164.92% ATR0.36
Employees131 Current Ratio1.70 Sales Q/Q-42.90% Oper. Margin- RSI (14)60.85 Volatility5.81% 7.05%
OptionableYes Debt/Eq- EPS Q/Q-60.90% Profit Margin- Rel Volume1.38 Prev Close5.34
ShortableYes LT Debt/Eq- EarningsFeb 09 AMC Payout- Avg Volume2.98M Price5.06
Recom2.00 SMA208.75% SMA5022.45% SMA20055.90% Volume4,127,695 Change-5.24%
Oct-06-16Resumed Jefferies Buy
Jun-21-16Downgrade Wells Fargo Outperform → Market Perform
May-06-16Upgrade Jefferies Hold → Buy
Dec-04-15Downgrade Wells Fargo Outperform → Market Perform
Jul-29-15Downgrade Jefferies Buy → Hold
Aug-27-14Downgrade R. F. Lafferty Buy → Neutral $4
Jan-08-14Initiated Chardan Capital Markets Buy $9
Oct-02-13Reiterated Oppenheimer Outperform $6 → $8
Sep-10-13Initiated R. F. Lafferty Buy $8
Jun-03-13Initiated WallachBeth Buy $6
Aug-31-11Initiated Summer Street Research Buy $8
Jul-28-11Initiated Summer Street Research Buy $8
Jul-13-11Resumed Brean Murray Buy $8
May-17-11Initiated Oppenheimer Outperform $6
Feb-23-11Initiated Wedbush Outperform $6
Jul-03-07Initiated Brean Murray Buy $8
Feb-20-07Initiated Lazard Capital Buy $6
Feb-21-17 08:45AM  IMMUNOMEDICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -5.24%
08:00AM  Immunomedics Files Federal Lawsuit Against venBio for Continuing Material Violations of the Federal Securities Laws GlobeNewswire
Feb-17-17 12:17PM  IMMUNOMEDICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
12:00PM  Immunomedics Presents Updated Results With Sacituzumab Govitecan (IMMU-132) in Heavily-Pretreated Patients With Metastatic Urothelial Cancer GlobeNewswire
11:21AM  VenBio Tries to Block Immunomedics Cancer Deal at Investopedia
Feb-16-17 05:02PM  IMMUNOMEDICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securiti
Feb-15-17 05:26PM  IMMUNOMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:15PM  Immunomedics Sends Letter to Stockholders Highlighting Value Creating Global Licensing Agreement, Underscoring Fulfillment of Promise to Stockholders GlobeNewswire
01:04PM  IMMUNOMEDICS INC Financials
11:34AM  Immunomedics, Inc. :IMMU-US: Earnings Analysis: Q2, 2017 By the Numbers : February 15, 2017
Feb-14-17 08:55PM  Seattle Genetics signs $2B licensing deal with Immunomedics for cancer drug at bizjournals.com
04:47PM  Immunomedics Comments on Baseless venBio Lawsuit GlobeNewswire
12:33PM  Activist Investor to Block Partnership of Immunomedics and Seattle Genetics at TheStreet
11:50AM  venBio Takes Steps to Protect Rights of Immunomedics Stockholders Business Wire
10:56AM  Activist Investor Seeks Legal Block of Immunomedics Cancer Drug Partnership With Seattle Genetics
01:55AM  Seattle Genetics Earnings: Waiting on ECHELON at Motley Fool
Feb-13-17 10:30AM  Heres Our Take On The Immunomedics, Inc. (IMMU) Deal at Insider Monkey
08:15AM  Blog Coverage Immunomedics Announces a $2 Billion Cancer Deal with Seattle Genetics Accesswire
Feb-12-17 11:35PM  Edited Transcript of IMMU earnings conference call or presentation 10-Feb-17 1:00pm GMT
03:01PM  Will Seattle Genetics' Deal With Immunomedics Get Scuttled? at Motley Fool
Feb-10-17 04:14PM  venBio Comments on Immunomedics Partnership Announcement Business Wire +21.63%
04:07PM  Could Seattle Genetics' Adcetris Grab 'Blockbuster Status' After 2017 Trial?
10:05AM  Immunomedics, Seattle Genetics Ink $2B Cancer Deal at Investopedia
09:14AM  Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News
08:26AM  IMMUNOMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:26AM  Immunomedics Announces Postponement of 2016 Annual Meeting PR Newswire
06:50AM  Immunomedics Enters into Exclusive Global Licensing Agreement with Seattle Genetics for Sacituzumab Govitecan (IMMU-132) with Potential Payments of up to Approximately $2 Billion, Plus Royalties PR Newswire
Feb-09-17 04:51PM  Immunomedics reports 2Q loss
04:36PM  IMMUNOMEDICS INC Files SEC form 10-Q, Quarterly Report
04:00PM  Immunomedics Announces Second Quarter Fiscal 2017 Results and Clinical Program Developments GlobeNewswire
08:00AM  Immunomedics Announces Conference Call and Webcast for Second Quarter Fiscal 2017 Results GlobeNewswire
Feb-07-17 03:37PM  IMMUNOMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -6.21%
12:45PM  Immunomedics Strongly Encourages Stockholders to Reject the venBio Nominees With Four New Independent Directors and a Robust Value-Maximization Process, Stockholders Should Not Risk Giving venBio Directors Control of the Immunomedics Boar GlobeNewswire
09:00AM  Glass Lewis Endorses Full Slate of venBio Nominees at Immunomedics Business Wire
Feb-06-17 06:58AM  ISS Endorses Full Slate of venBio Nominees at Immunomedics Business Wire
Feb-02-17 04:15PM  Immunomedics Mails Letter to Stockholders Highlighting Strength of New Board and Deep Engagement in Robust, Value-Creating Strategic and CMC Processes GlobeNewswire
Jan-30-17 09:08AM  IMMUNOMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
09:00AM  venBio Calls on Immunomedics Stockholders to Support Meaningful Change Business Wire
09:00AM  Immunomedics Sets the Record Straight in New Presentation GlobeNewswire
Jan-27-17 08:13AM  Biotech Stock Mailbag: Trump, Aurinia, Immunomedics, Cellceutix
07:11AM  IMMUNOMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  Immunomedics Issues Statement to Stockholders and Files Investor Presentation GlobeNewswire
Jan-26-17 05:23PM  Immunomedics Shares Ride Roller Coaster on Whether It's for Sale
08:00AM  venBio Releases Presentation Detailing Urgent Case for Change at Immunomedics Business Wire
Jan-25-17 10:55AM  Immunomedics Sale Hinges on Proxy Battle Over Fate of Controversial Founder +6.90%
Jan-24-17 07:01AM  IMMUNOMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  Immunomedics Mails Letter to Stockholders GlobeNewswire
Jan-20-17 08:45AM  Immunomedics (IMMU) Worth a Look: Stock Climbs 7%
Jan-18-17 05:20PM  CORRECTING and REPLACING venBio Sends Letter to Immunomedics Stockholders Business Wire +7.20%
01:36PM  IMMUNOMEDICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
01:00PM  Immunomedics Highlights Expanded Pipeline Positioning Company for Sustained Value Creation GlobeNewswire
09:00AM  Immunomedics Announces New Data for IMMU-132 at Investor R&D Day GlobeNewswire
Jan-12-17 04:07PM  IMMUNOMEDICS INC Files SEC form 8-K, Change in Directors or Principal Officers +9.78%
03:48PM  Thursdays Biggest Biopharma Winners
07:00AM  Immunomedics to Mail Letter to Stockholders Highlighting Unprecedented Progress Toward Enhanced Value Creation GlobeNewswire
Jan-11-17 09:00AM  venBio Sends Letter to Immunomedics Stockholders Business Wire
Jan-10-17 08:00AM  venBio Responds to Immunomedics Announcement Business Wire
Jan-09-17 10:00AM  Immunomedics Announces Antitumor Effect of Sacituzumab Govitecan (IMMU-132) in Triple-Negative Breast Cancer Can be Enhanced With DNA-Repair Inhibitors GlobeNewswire -6.70%
08:23AM  IMMUNOMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
06:00AM  Immunomedics Announces Reconstituted Board of Directors and Leadership Succession Plan GlobeNewswire
Jan-05-17 07:00AM  Immunomedics Announces Investor R&D Day on January 18, 2017 GlobeNewswire
Dec-31-16 12:01AM  [$$] We misstated a date. at Barrons.com
Dec-30-16 10:00AM  Immunomedics Completes Enrollment In Cancer Drug Study
Dec-27-16 07:00AM  Immunomedics Announces Achievement of Patient Enrollment Into Single-Arm Phase 2 Study With Sacituzumab Govitecan (IMMU-132) in Triple-Negative Breast Cancer GlobeNewswire
Dec-24-16 12:01AM  [$$] Private Equity Investor venBio Likes Immunomedics at Barrons.com
Dec-22-16 07:03AM  Immunomedics Awarded Additional Intellectual Property Protection for IMMU-140, an Antibody-Drug Conjugate With Dual-Therapeutic Potential GlobeNewswire
Dec-21-16 12:29PM  ETFs with exposure to Immunomedics, Inc. : December 21, 2016
Dec-12-16 08:56AM  IMMUNOMEDICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits +5.69%
07:00AM  Immunomedics Announces Novel Immuno-Oncology Program Targeting Trop-2-Expressing Cancers GlobeNewswire
Dec-07-16 01:33PM  Does Immunomedics, Inc. (IMMU)s New Candidate IMMU-140 Stand A Chance Of Success? at Insider Monkey
Dec-06-16 07:00AM  Immunomedics Introduces New Antibody-Drug Conjugate at Annual Meeting of American Society of Hematology GlobeNewswire +10.06%
Dec-02-16 04:40PM  Immunomedics, Inc. (IMMU): The Smart Money Is Quietly Loading Up On This Stock at Insider Monkey
Nov-29-16 09:00AM  venBio Responds to Immunomedics Postponement of Annual Meeting Business Wire
Nov-28-16 07:18AM  IMMUNOMEDICS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, F
07:00AM  Immunomedics Postpones 2016 Annual Meeting of Stockholders GlobeNewswire
Nov-22-16 09:00AM  venBio Comments on its Recent Nomination of Four Highly-Qualified Candidates for Board of Immunomedics, Inc. Business Wire +6.91%
Nov-18-16 04:15PM  Immunomedics Comments on Receipt of Director Nominations GlobeNewswire +5.00%
Nov-15-16 07:00AM  Immunomedics Expands Antibody-Drug Conjugate Program to Potentially Address Most of Human Cancers GlobeNewswire
Nov-14-16 03:30PM  Immunomedics to Provide Clinical Update on Sacituzumab Govitecan (IMMU-132) in Triple-Negative Breast Cancer at San Antonio Breast Cancer Symposium GlobeNewswire +5.06%
Nov-08-16 12:10PM  ETFs with exposure to Immunomedics, Inc. : November 8, 2016
Nov-07-16 11:12AM  Immunomedics, Inc. :IMMU-US: Earnings Analysis: Q1, 2017 By the Numbers : November 7, 2016
Nov-04-16 07:00AM  Immunomedics Receives Edison Patent Award From Research & Development Council of New Jersey for the Fourth Time GlobeNewswire +5.69%
Nov-03-16 12:37PM  Edited Transcript of IMMU earnings conference call or presentation 2-Nov-16 9:00pm GMT -6.22%
08:15AM  Blog Coverage Celldex Acquires Cancer Medicine Company for $62.5 Million Accesswire
Nov-02-16 06:09PM  Immunomedics reports 1Q loss
04:02PM  IMMUNOMEDICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:01PM  Immunomedics Announces First Quarter Fiscal 2017 Results and Clinical Program Developments GlobeNewswire
07:07AM  Q1 2017 Immunomedics Inc Earnings Release - After Market Close
Oct-27-16 07:00AM  Immunomedics Announces Conference Call and Webcast for First Quarter Fiscal 2017 Results GlobeNewswire
Oct-24-16 04:30PM  Immunomedics Engages Greenhill & Co. as Strategic Advisor GlobeNewswire
Oct-19-16 07:00AM  Immunomedics Announces New Patents for Antibody-Drug Conjugates and Vaccines for Cancer Therapy GlobeNewswire
Oct-18-16 05:16PM  IMMUNOMEDICS INC Files SEC form 8-K, Change in Directors or Principal Officers
Oct-12-16 04:39PM  IMMUNOMEDICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
12:31PM  Is Immunomedics Inc. Still a Strong Buy? at Motley Fool
09:51AM  ETFs with exposure to Immunomedics, Inc. : October 12, 2016
09:05AM  Immunomedics Announces Closing of $30 Million Financing GlobeNewswire
Oct-11-16 05:21PM  IMMUNOMEDICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Oct-08-16 10:20AM  8 Analyst Stock Picks Under $10 for Massive Upside at 24/7 Wall St.
09:55AM  5 Companies That Destroyed Shareholders This Past Week at 24/7 Wall St.
Oct-06-16 11:43AM  Jefferies Sees Accelerated Approval Of Immunomedics' IMMU-132 'Not A Stretch'
Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and epratuzumab, a humanized antibody that targets CD22, an antigen found on the surface of B lymphocytes. Its early-stage products include IMMU-114, a novel humanized antibody for the treatment of patients with B-cell and other cancers; Milatuzumab, a humanized monoclonal antibody targeting tumors that expresses the CD74 antigen, which is present on various hematological tumors and solid cancers; Veltuzumab, a humanized monoclonal antibody targeting CD20 receptors on B lymphocytes for the treatment of non-Hodgkin lymphoma and autoimmune diseases; and Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled anti-CD22 investigational product. The company also provides LeukoScan, a diagnostic imaging product for diagnostic imaging to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stark Don CDirectorAug 24Sale2.979,90029,45155,848Aug 25 05:00 PM
PAETZOLD MARY EDirectorAug 23Option Exercise1.9615,00029,40082,474Aug 25 05:00 PM
MARKISON BRIAN ADirectorAug 23Option Exercise1.9615,00029,40090,446Aug 25 05:01 PM
MARKISON BRIAN ADirectorAug 23Sale2.9815,00044,63475,446Aug 25 05:01 PM
PAETZOLD MARY EDirectorAug 23Sale2.9815,00044,67367,474Aug 25 05:00 PM
Stark Don CDirectorAug 10Option Exercise1.9615,00029,40065,748Aug 12 04:00 PM
GOLDENBERG CYNTHIA LPresident and CEOJun 13Option Exercise2.63139,950368,0695,375,412Jun 14 05:00 PM
GOLDENBERG CYNTHIA LPresident and CEOJun 13Option Exercise2.63128,674338,413767,744Jun 14 05:00 PM
GOLDENBERG DAVID MCSO & Chairman of the BODJun 13Option Exercise2.63128,674338,4133,438,055Jun 14 05:01 PM
GOLDENBERG DAVID MCSO & Chairman of the BODJun 13Option Exercise2.63139,950368,0692,631,691Jun 14 05:01 PM
GOLDENBERG DAVID MCSO & Chairman of the BODJun 13Sale3.02128,674389,2003,309,381Jun 14 05:01 PM
GOLDENBERG DAVID MCSO & Chairman of the BODJun 13Sale3.02139,950422,6212,491,741Jun 14 05:01 PM
GOLDENBERG CYNTHIA LPresident and CEOJun 13Sale3.02139,950422,6215,235,462Jun 14 05:00 PM
GOLDENBERG CYNTHIA LPresident and CEOJun 13Sale3.02128,674389,200639,070Jun 14 05:00 PM
GOLDENBERG CYNTHIA LPresident and CEOJun 10Option Exercise2.5192,040231,4075,327,502Jun 14 05:00 PM
GOLDENBERG CYNTHIA LPresident and CEOJun 10Option Exercise2.6311,32629,787650,396Jun 14 05:00 PM
GOLDENBERG DAVID MCSO & Chairman of the BODJun 10Option Exercise2.6311,32629,7873,320,707Jun 14 05:01 PM
GOLDENBERG DAVID MCSO & Chairman of the BODJun 10Option Exercise2.5192,040231,4072,583,781Jun 14 05:01 PM
GOLDENBERG DAVID MCSO & Chairman of the BODJun 10Sale3.0711,32634,7813,309,381Jun 14 05:01 PM
GOLDENBERG DAVID MCSO & Chairman of the BODJun 10Sale3.0592,040281,1552,491,741Jun 14 05:01 PM
GOLDENBERG CYNTHIA LPresident and CEOJun 10Sale3.0592,040281,1555,235,462Jun 14 05:00 PM
GOLDENBERG CYNTHIA LPresident and CEOJun 10Sale3.0711,32634,781639,070Jun 14 05:00 PM
GOLDENBERG CYNTHIA LPresident and CEOJun 08Option Exercise2.50120,388300,9705,355,850Jun 08 09:14 PM
GOLDENBERG CYNTHIA LPresident and CEOJun 08Option Exercise2.5341,441104,903680,511Jun 08 09:14 PM
GOLDENBERG DAVID MCSO & Chairman of the BODJun 08Option Exercise2.5341,441104,9033,350,892Jun 08 09:13 PM
GOLDENBERG DAVID MCSO & Chairman of the BODJun 08Option Exercise2.50120,388300,9702,612,129Jun 08 09:13 PM
GOLDENBERG DAVID MCSO & Chairman of the BODJun 08Sale3.6241,441150,2193,309,381Jun 08 09:13 PM
GOLDENBERG DAVID MCSO & Chairman of the BODJun 08Sale3.64120,388438,7782,491,741Jun 08 09:13 PM
GOLDENBERG CYNTHIA LPresident and CEOJun 08Sale3.64120,388438,7785,235,462Jun 08 09:14 PM
GOLDENBERG CYNTHIA LPresident and CEOJun 08Sale3.6241,441150,219639,070Jun 08 09:14 PM
GOLDENBERG DAVID MCSO & Chairman of the BODJun 07Option Exercise2.504,60011,5003,313,981Jun 08 09:13 PM
GOLDENBERG DAVID MCSO & Chairman of the BODJun 07Option Exercise2.5012,30030,7502,504,041Jun 08 09:13 PM
GOLDENBERG CYNTHIA LPresident and CEOJun 07Option Exercise2.5012,30030,7505,247,762Jun 08 09:14 PM
GOLDENBERG CYNTHIA LPresident and CEOJun 07Option Exercise2.504,60011,500643,670Jun 08 09:14 PM
GOLDENBERG CYNTHIA LPresident and CEOJun 07Sale3.9812,30048,9545,235,462Jun 08 09:14 PM
GOLDENBERG CYNTHIA LPresident and CEOJun 07Sale4.014,60018,427639,070Jun 08 09:14 PM
GOLDENBERG DAVID MCSO & Chairman of the BODJun 07Sale4.014,60018,4273,309,381Jun 08 09:13 PM
GOLDENBERG DAVID MCSO & Chairman of the BODJun 07Sale3.9812,30048,9542,491,741Jun 08 09:13 PM
GOLDENBERG DAVID MCSO & Chairman of the BODJun 06Option Exercise2.5063,959159,8983,373,340Jun 08 09:13 PM
GOLDENBERG DAVID MCSO & Chairman of the BODJun 06Option Exercise2.50110,322275,8052,602,063Jun 08 09:13 PM
GOLDENBERG CYNTHIA LPresident and CEOJun 06Option Exercise2.50110,322275,8055,345,784Jun 08 09:14 PM
GOLDENBERG CYNTHIA LPresident and CEOJun 06Option Exercise2.5063,959159,898703,029Jun 08 09:14 PM
GOLDENBERG CYNTHIA LPresident and CEOJun 06Sale4.09110,322451,0075,235,462Jun 08 09:14 PM
GOLDENBERG CYNTHIA LPresident and CEOJun 06Sale4.0963,959261,880639,070Jun 08 09:14 PM
GOLDENBERG DAVID MCSO & Chairman of the BODJun 06Sale4.0963,959261,8803,309,381Jun 08 09:13 PM
GOLDENBERG DAVID MCSO & Chairman of the BODJun 06Sale4.09110,322451,0072,491,741Jun 08 09:13 PM